NASDAQ: TRXB · Life Sciences · 5 alerts · CIK 2139097
Share price
$10.77Close, Nov 16
Market cap
$310M
Shares outstanding
28.79MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All TRex Bio, Inc. filings on SEC EDGAR ↗
TRex Bio, Inc. is a clinical-stage biopharmaceutical company that has incurred substantial losses since inception and expects these losses to increase as it develops its autoimmune and inflammatory disease product candidates. As of November 5, 2026, the company had 28,788,654 shares of common stock outstanding and is classified as an emerging growth company.
TRex Bio reported financial results for the third quarter of 2026, highlighting a net loss of $14.1 million and a cash position of $154.2 million. The company recently completed a $133.5 million IPO in October 2026, which extends its expected cash runway into the second half of 2029 to support its clinical pipeline, including TRB-061 and TRB-071.
Term
Q3 2026
“The positive Phase 1a results for TRB-061 demonstrated selective activation and expansion of immunoregulatory Tregs in humans, providing clinical evidence that we believe supports this approach. We are now focused on understanding whether these effects can translate into meaningful and durable disease control for patients with atopic dermatitis.”
Johnston Erwin, Chief Executive Officer of TRexBio
“With the completion of our IPO, we have the resources to advance TRB-061 toward its planned mid-2027 clinical readout and expect to bring TRB-071, which targets a distinct Treg pathway, into the clinic in the first half of 2027.”
Johnston Erwin, Chief Executive Officer of TRexBio
TRex Bio Insider Alexandria Venture Investments LLC Buys $2.5M of Stock
Alexandria Venture Investments LLC bought 178,571 shares of TRex Bio, Inc. at $14.00 a share, worth $2.5M in total on Oct 13, 2026. Shares held after the trade: 1,346,501 (+15.3%).
TRex Bio, Inc. filed its fourth amended and restated certificate of incorporation and second amended and restated bylaws in connection with the closing of its initial public offering. The amendments authorize 225 million shares of common stock and 25 million shares of preferred stock while establishing new procedures for stockholder proposals and director nominations.
Svlsf VI LLC bought 92,857 shares of TRex Bio, Inc. at $14.00 a share, worth $1.3M in total on Oct 8, 2026. Shares held after the trade: 7,356 (+71.8%).